Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $2.33.
Several research analysts have weighed in on the company. BTIG Research reaffirmed a “buy” rating and issued a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Rodman & Renshaw assumed coverage on Nektar Therapeutics in a research report on Friday, June 28th. They issued a “buy” rating and a $2.00 target price on the stock.
Read Our Latest Analysis on NKTR
Institutional Trading of Nektar Therapeutics
Nektar Therapeutics Trading Up 1.6 %
NASDAQ:NKTR opened at $1.30 on Friday. The firm has a market capitalization of $239.23 million, a price-to-earnings ratio of -1.41 and a beta of 0.60. Nektar Therapeutics has a 1-year low of $0.41 and a 1-year high of $1.93. The business’s fifty day moving average price is $1.24 and its 200 day moving average price is $1.32.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). The business had revenue of $23.49 million for the quarter, compared to analyst estimates of $17.24 million. Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. During the same period in the previous year, the firm posted ($0.27) earnings per share. Equities analysts forecast that Nektar Therapeutics will post -0.85 earnings per share for the current year.
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Read More
- Five stocks we like better than Nektar Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- How to Capture the Benefits of Dividend Increases
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- Industrial Products Stocks Investing
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.